<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Azilsartan medoxomil</strong></td></tr><tr><th>Accession Number</th><td><strong>DB08822</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Azilsartan medoxomil is an angiotensin II receptor antagonist indicated for the treatment of mild to moderate essential hypertension. Azilsartan medoxomil is a prodrug of Azilsartan marketed as &#8220;Edarbi&#8221; by Takeda. Azilsartan medoxomil has so far been shown to be superior to olmesartan and valsartan in lowering blood pressure.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB08822/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB08822/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08822.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08822.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08822.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08822.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB08822.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB08822">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Azilsartan</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Azilsartan kamedoxomil</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Azilsartan medoxomilo</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Azilsartanum medoxomilum</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Edarbi</td><td>Takeda</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Edarbyclor</td><td>Chlorthalidone + Azilsartan medoxomil</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/angiotensin-receptor-antagonists">Angiotensin Receptor Antagonists</a></li></ul></td></tr><tr><th>CAS number</th><td>147403-03-0</td></tr><tr><th>Weight</th><td>Average: 568.5336<br>Monoisotopic: 568.159413764</td></tr><tr><th>Chemical Formula</th><td>C<sub>30</sub>H<sub>24</sub>N<sub>4</sub>O<sub>8</sub></td></tr><tr><th>InChI Key</th><td>QJFSABGVXDWMIW-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(5-methyl-2-oxo-2H-1,3-dioxol-4-yl)methyl 2-ethoxy-1-({4-[2-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-7-carboxylate</div></td></tr><tr><th>SMILES</th><td><div class="wrap">CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NOC(=O)N1)C(=CC=C2)C(=O)OCC1=C(C)OC(=O)O1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Biphenyls and Derivatives</td></tr><tr><th>Direct parent</th><td>Biphenyls and Derivatives</td></tr><tr><th>Alternative parents</th><td>Benzoic Acid Esters; Benzylethers; Benzimidazoles; Benzoyl Derivatives; Alkyl Aryl Ethers; N-substituted Imidazoles; Oxadiazoles; Carboxylic Acid Esters; Dialkyl Ethers; Enolates; Polyamines</td></tr><tr><th>Substituents</th><td>benzoate ester; benzylether; benzimidazole; benzoic acid or derivative; benzoyl; alkyl aryl ether; n-substituted imidazole; oxadiazole; imidazole; azole; carboxylic acid ester; dialkyl ether; carboxylic acid derivative; ether; enolate; polyamine; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the biphenyls and derivatives. These are organic compounds containing to benzene rings linked together by a C-C bond.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treatment of hypertension (alone or as an adjunct).</td></tr><tr><th>Pharmacodynamics</th><td>Azilsartan medoxomil decreases the pressor effect of angiotensin II. In response, angiotensin I, angiotensin II, and renin are increased while aldosterone is decreased.</td></tr><tr><th>Mechanism of action</th><td>Azilsartan medoxomil blocks the angiotensin II type 1 receptor preventing angiotensin II from binding and causing vasoconstriction. Azilsartan's ability to remain tightly bound to AT1 receptors for very long periods after drug washout is among its most unusual features. </td></tr><tr><th>Absorption</th><td>Azilsartan medoxomil is hydrolyzed to the active metabolite azilsartan in the GI tract. The presence of food does not affect oral absorption of azilsartan medoxomil, and the bioavailability is 60% for azilsartan. Maximum plasma concentrations are reached in 1.5 to 3 hours.</td></tr><tr><th>Volume of distribution</th><td><p>Azilsartan medoxomil has a Vd of 16L.</p></td></tr><tr><th>Protein binding</th><td>Azilsartan medoxomil is 99% plasma protein bound.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Azilsartan is metabolized by CYP2C9. CYP2C9 carries out decarboxylation of azilsartan to M-I, and O-dealkylation of azilsartan to M-II. Both M-I and M-II have no pharmacologic activity. </p></td></tr><tr><th>Route of elimination</th><td>Renal clearance is 2.3 L/minute.</td></tr><tr><th>Half life</th><td>The half-life is 11 hours, and it takes about 5 days to reach steady state concentrations.</td></tr><tr><th>Clearance</th><td><p>Fecal elimination accounts for 55%, urine excretion 42%, and unchanged drug 15%.</p></td></tr><tr><th>Toxicity</th><td>Hypotension and diarrhea are most common.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.915</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5843</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5619</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5061</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7217</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8851</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.834</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8338</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5128</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7445</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.5531</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8779</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5915</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.8507</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.594</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.5227
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.7059
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9962
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5320 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8853
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.6952
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>40 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>80 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>212-214</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>water solubility</td><td>practically insoluble</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>pKa</td><td>6.1</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>7.03e-03 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>4.94</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>6.03</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.9</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>9.21</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>1.75</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>7</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>139.57</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>10</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>149.52</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>57.73</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>6</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>0</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T: Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem. 1996 Dec 20;39(26):5228-35.</p></span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Jones JD, Jackson SH, Agboton C, Martin TS: Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker. P T. 2011 Oct;36(10):634-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22346296">Pubmed</a></li>
	<li>Lanier G, Sankholkar K, Aronow WS: Azilsartan, Aliskiren, and Combination Antihypertensives Utilizing Renin-Angiotensin-Aldosterone System Antagonists. Am J Ther. 2012 Sep 12. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22975662">Pubmed</a></li>
	<li>Kurtz TW, Kajiya T: Differential pharmacology and benefit/risk of azilsartan compared to other sartans. Vasc Health Risk Manag. 2012;8:133-43. doi: 10.2147/<span class="caps">VHRM</span>.S22595. Epub 2012 Feb 28. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22399858">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D08865" target="_blank">D08865 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=68845" target="_blank">68845 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL2028661" target="_blank">CHEMBL2028661 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/edarbi-drug.htm" target="_blank">http://www.rxlist.com/edarbi-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/ingredient/azilsartan-medoxomil.html" target="_blank">http://www.drugs.com/ingredient/azilsartan-medoxomil.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Azilsartan" target="_blank">Azilsartan <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C09CA09<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C09#C09">C09 &#8212; AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM</a></li><li><a href="/atc/C09C#C09C">C09C &#8212; ANGIOTENSIN II ANTAGONISTS, PLAIN</a></li><li><a href="/atc/C09CA#C09CA">C09CA &#8212; Angiotensin II antagonists, plain</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:32.08</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB08822.pdf?1356121149">show</a>(381 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB08822.pdf?1367873588">show</a>(34.9 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00945">Acetylsalicylic acid</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB01258">Aliskiren</a></td><td>Azilsartan medoxomil used in combination with aliskiren may lead to hyperkalemia, hypotension, and nephrotoxicity.</td></tr><tr><td><a href="/drugs/DB01143">Amifostine</a></td><td>Azilsartan medoxomil used in combintation with amifostine may lead to hypotension.</td></tr><tr><td><a href="/drugs/DB06237">Avanafil</a></td><td>Pharmacodynamic synergist- increases effects. </td></tr><tr><td><a href="/drugs/DB00542">Benazepril</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB01197">Captopril</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB00482">Celecoxib</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB04272">Citric Acid</a></td><td>Increases serum potassium. </td></tr><tr><td><a href="/drugs/DB00586">Diclofenac</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00861">Diflunisal</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00584">Enalapril</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB00749">Etodolac</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB01276">Exenatide</a></td><td>Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity. </td></tr><tr><td><a href="/drugs/DB00573">Fenoprofen</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00712">Flurbiprofen</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00492">Fosinopril</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB01050">Ibuprofen</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00328">Indomethacin</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB01009">Ketoprofen</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00465">Ketorolac</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB06655">Liraglutide</a></td><td>Pharmacodynamic synergist- increases effects. May also increase hypoglycemic effects by improving insulin sensitivity. </td></tr><tr><td><a href="/drugs/DB00722">Lisinopril</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB01356">Lithium</a></td><td>Azilsartan medoxomil may increase lithium serum concentrations.</td></tr><tr><td><a href="/drugs/DB04835">Maraviroc</a></td><td>Pharmacodynamic synergist- increases effects.</td></tr><tr><td><a href="/drugs/DB00939">Meclofenamic acid</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00784">Mefenamic acid</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00814">Meloxicam</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00691">Moexipril</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB00461">Nabumetone</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00788">Naproxen</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00727">Nitroglycerin</a></td><td>Pharmacodynamic synergist- increases effects.</td></tr><tr><td><a href="/drugs/DB00991">Oxaprozin</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00790">Perindopril</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB00554">Piroxicam</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00881">Quinapril</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB00178">Ramipril</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr><tr><td><a href="/drugs/DB00073">Rituximab</a></td><td>Azilsartan medoxomil used in combination with rituximab may lead to hypotension.</td></tr><tr><td><a href="/drugs/DB00795">Sulfasalazine</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00605">Sulindac</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00820">Tadalafil</a></td><td>Pharmacodynamic synergist- increases effects.</td></tr><tr><td><a href="/drugs/DB00500">Tolmetin</a></td><td>Increases toxicity of each. May deteriorate renal function, particularly in volume depleted or elderly patients. Decreases effects of azilsartan by antagonism. </td></tr><tr><td><a href="/drugs/DB00519">Trandolapril</a></td><td>Pharmacodynamic synergism: dual blockade of renin-angiotensin system. Increases risks of hypotension, hyperkalemia, renal impairment.  </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Food does not affect absorption or bioavailibity.</li>
<li>Nutrition/Herbal interaction</li></ul></td></tr></tbody></table>